CME credits: 1.00

Valid until: 26-09-2025

Claim your CME credit at https://reachmd.com/programs/cme/late-stage-bispecifics-and-adcs-in-dlbcl/15182/

This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b#:~:text=On%20May%2019%2C%202023%2C%20the,or%20more%20lines%20of%20systemic

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. To learn more about this approval please visit: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell